The Division of Workers’ Compensation (DWC) has issued a Notice of Public Hearing for proposed evidence-based update and adoption to the Medical Treatment Utilization Schedule (MTUS), which can be found at California Code of Regulations, title 8, update to section 9792.24.2 and adoption of section 9792.24.8.
The proposed evidence-based updates and adoption to the MTUS incorporate by reference the latest published guidelines from the American College of Occupational and Environmental Medicine (ACOEM) for the following:
– – Proposed Amendment to Section 9792.24.2. Chronic Pain Guidelines. (ACOEM December 19, 2024)
– – Proposed Adoption of Section 9792.24.8 Cannabis Guideline (ACOEM January 28, 2025)
The proposed evidence-based update and adoption to the MTUS regulations are exempt from Labor Code sections 5307.3 and 5307.4 and the rulemaking provisions of the Administrative Procedure Act. DWC is required under Labor Code section 5307.27 to have a 30-day public comment period, hold a public hearing, and respond to all the comments received during the public comment period prior to publishing the order adopting the update online.
Members of the public may review and comment on the proposed updates. Written comments must be submitted no later than March 14, 2025.
Members of the public may attend the virtual and conference call public hearing
– – Time: March 14, 2025 10 a.m. Pacific Time (US and Canada)
– – Join from PC, Mac, Linux, iOS or Android: https://dir-ca-gov.zoom.us/j/86193231447
Of interest is the Summary of Recommendations seen on page 1 of the proposed Cannabis Guideline (ACOEM January 28, 2025). The Guideline reported that adverse effects of the use of Cannabis are “common.” It continued for the next several pages to list perhaps more than 100 of them. It goes on to elaborate on each topic.
Unsurprisingly, the weight of this evidence supported this overall recommendation:
– – Cannabinoids for Chronic Pain – Not Recommended – Evidence C
– – Cannabinoids for Acute Pain – Not Recommended – Evidence C
– – Cannabinoids for Chronic Pain – Moderately Not Recommended – Evidence B
– – Cannabinoids for Safety-Critical Workers – Not Recommended – Evidence C